A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.
Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV · 2000 · FEBS letters
What does this source report?
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
- Population and setting
- Human leukemia cell lines; porcine marrow-derived peptide
- Evidence type
- In vitro
- Preparation
- See the original report; formulation details require verification.
- Source language
- English indexed abstract; original language: eng
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV. A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. FEBS letters 2000.
Molekul research summary: https://molekul.io/research/rp-10745082. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry